Efficacy of stereotactic body radiotherapy in primary renal cell carcinoma

Feasibility of Stereotactic Body Radiotherapy in Patients with Small Renal Cell Carcinoma Who are Unfit for Definitive Surgery: Phase 2 Study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CRIS

Registry ID

KCT0007835

Enrollment

Registered

2022-10-21

Start date

2020-01-17

Completion date

Unknown

Last updated

2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Radiation : All patients were treated using CyberKnife ver. 9.5. (Accuray Inc., Sunnyvale, CA, USA). Three gold fiducial markers were implanted close to the renal tumor to use the Synchrony system for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? A patient diagnosed with renal cell carcinoma of T1aN0M0 (size 4 cm or less) by imaging examination. ? Patients who are difficult to apply surgical treatment due to one of the following conditions. ? Elderly patients aged 75 years or older ? Those with ECOG behavior level 2 or higher ? Those with a Charlson comorbidity index of 3 or higher. ? Those who refused surgical treatment. ? Those who agreed to the clinical trial ? Those who have not received systemic treatment for renal cell carcinoma

Exclusion criteria

Exclusion criteria: ? Those who did not consent to the clinical trial. ? Those who have not performed the imaging test. ? Those with clinical stage T1b or higher. ? Those who have lymph nodes (N1) or distant metastases (M1) on imaging tests. ? Those who have undergone systemic treatment for renal cell carcinoma.

Design outcomes

Primary

Measure	Time frame
Change in tumor size	—

Secondary

Measure	Time frame
kidney function	—

Countries

Korea, Republic of

Contacts

Public ContactDongsu Kim

Asan Medical Center

yunbung@daum.net+82-2-3010-5992

Outcome results